Lets Talk About Endari
TANA
2919 Metairie Road
Metairie, LA 70001
Wednesday, March 11, 2026 at 6:15pm CT - 9:00pm CT
Info
Additional Information
This is our second dinner for the month of March.
Please only sign up for one dinner for March to give others a chance to register.
This educational program examines the clinical role of Endari® (L-glutamine oral
powder), in the management of Sickle Cell Disease (SCD). The
program will review the FDA-approved indication to reduce acute complications of SCD in adult
and pediatric patients 5 years of age and older, including clinical trial data regarding reduction of
sickle cell crises and hospitalizations.
The product’s mechanism of action, administration instructions, and its established safety profile
will also be discussed to support informed clinical decision making.
powder), in the management of Sickle Cell Disease (SCD). The
program will review the FDA-approved indication to reduce acute complications of SCD in adult
and pediatric patients 5 years of age and older, including clinical trial data regarding reduction of
sickle cell crises and hospitalizations.
The product’s mechanism of action, administration instructions, and its established safety profile
will also be discussed to support informed clinical decision making.
Target Audience:
This program is intended for healthcare providers included in the care of patients with Sickle
Cell Disease (SCD), including nurse practitioners, physicians, physicians assistants.
The information is relevant for providers practicing in primary care, family medicine,
hematology, general practice, and any emergency setting where acute and chronic SCD
management occurs.
Learning Objectives:
Brief overview of Sickle Cell Disease – Understanding the Science
The Role of Endari® (L-glutamine oral powder) in SCD
Clinical Endari® (L-glutamine oral powder)
Assessment of the Established Safety Profile
Clinical Integration for Healthcare Providers
This program is intended for healthcare providers included in the care of patients with Sickle
Cell Disease (SCD), including nurse practitioners, physicians, physicians assistants.
The information is relevant for providers practicing in primary care, family medicine,
hematology, general practice, and any emergency setting where acute and chronic SCD
management occurs.
Learning Objectives:
Brief overview of Sickle Cell Disease – Understanding the Science
The Role of Endari® (L-glutamine oral powder) in SCD
Clinical Endari® (L-glutamine oral powder)
Assessment of the Established Safety Profile
Clinical Integration for Healthcare Providers